Gilead Sciences (GILD) 103.96 $GILD
'Fast Money' Recap: Will Apple Shares Pull Back?
at The Street - Sat Aug 23, 4:00AM CDT
The trading panel discussed the company's all-time high and how to trade following Janet Yellen's Jackson Hole comments.
Most active Nasdaq-traded stocks
AP - Fri Aug 22, 5:03PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Final Glance: Biotechnology companies
AP - Fri Aug 22, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Bristol-Myers/Pfizer's Eliquis Gets Yet Another FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 4:55PM CDT
Bristol-Myers (BMY) and partner Pfizer (PFE) announced that the FDA has cleared Eliquis for an additional indication.
Data on Celgene's Revlimid Published in Oncology Journal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 4:35PM CDT
Encouraging data was published on Celgen's (CELG) Revlimid in DLBCL.
3 Reasons Bristol-Myers Squibb's Stock Could Rise
George Budwell, The Motley Fool - Motley Fool - Fri Aug 22, 3:47PM CDT
The patent cliff has forced most Big Pharmas to make major transformations in their businesses over the past few years. Bristol-Myers Squibb in particular has been ravaged by the loss of patent protection for blood thinner Plavix and a host of...
Amgen Upgraded to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 3:40PM CDT
On Aug 21, Zacks Investment Research upgraded Amgen Inc. (AMGN) to a Zacks Rank #1 (Strong Buy).
Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 1.65%
Comtex SmarTrend(R) - Fri Aug 22, 3:37PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $102.61 to a high of $105.16. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $102.57 on volume of 13.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Look for Shares of Gilead Sciences to Potentially Pullback after Yesterday's 1.65% Rise
Comtex SmarTrend(R) - Fri Aug 22, 3:36PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $102.61 to a high of $105.16. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $102.57 on volume of 13.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Midday Glance: Biotechnology companies
AP - Fri Aug 22, 12:22PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Next Resistance Level for Gilead Sciences (GILD) is $103.26
Comtex SmarTrend(R) - Fri Aug 22, 9:02AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) have bullishly opened above the pivot of $101.81 today and have reached the first resistance level of $102.77. Investors may be interested in a cross of the next upside pivot targets of $103.26 and $104.71.
Repros Therapeutics (RPRX) Shows Strength: Stock Rises 5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 8:39AM CDT
Repros Therapeutics Inc. (RPRX) was a big mover last session, as its shares rose a little over 5% on the day.
Why Gilead Sciences (GILD) Could Beat Earnings Estimates Again - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 7:49AM CDT
Gilead Sciences has seen a nice streak of beating earnings estimates at the previous two reports, suggesting it has a nice short-term history of crushing expectations and that it could be a great candidate for another beat.
Jim Cramer's 'Mad Money' Recap: 12 Stocks Even Better Than Google
at The Street - Thu Aug 21, 6:59PM CDT
Google is fabulous, Cramer says, but these stocks are just as good if not better.
Bristol-Myers, Celgene Pair Up for Oncology Combo Treatments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 4:20PM CDT
Bristol-Myers (BMY) inked an oncology deal with Celgene (CELG).
Achillion Attains 52-Week High on ACH-3102 Patent Protection - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 4:00PM CDT
Achillion's (ACHN) shares touched a 52-week high of $10.18 on Aug 20 following its announcement that the USPTO has granted a patent to the company.
Amicus Therapeutics (FOLD) Soars on Fabry Drug Trial Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 3:55PM CDT
Amicus Therapeutics (FOLD) announced positive data from its second phase III study on migalastat.
Jim Cramer's Stop Trading: Don't Worry About Gilead Sciences
at The Street - Thu Aug 21, 10:10AM CDT
TheStreet's Jim Cramer says investors should not worry about Gilead Sciences, especially considering its low valuation.
'Fast Money' Recap: Will Apple Shares Pull Back?
at The Street - Sat Aug 23, 4:00AM CDT
The trading panel discussed the company's all-time high and how to trade following Janet Yellen's Jackson Hole comments.
Most active Nasdaq-traded stocks
AP - Fri Aug 22, 5:03PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Final Glance: Biotechnology companies
AP - Fri Aug 22, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Bristol-Myers/Pfizer's Eliquis Gets Yet Another FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 4:55PM CDT
Bristol-Myers (BMY) and partner Pfizer (PFE) announced that the FDA has cleared Eliquis for an additional indication.
Data on Celgene's Revlimid Published in Oncology Journal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 4:35PM CDT
Encouraging data was published on Celgen's (CELG) Revlimid in DLBCL.
3 Reasons Bristol-Myers Squibb's Stock Could Rise
George Budwell, The Motley Fool - Motley Fool - Fri Aug 22, 3:47PM CDT
The patent cliff has forced most Big Pharmas to make major transformations in their businesses over the past few years. Bristol-Myers Squibb in particular has been ravaged by the loss of patent protection for blood thinner Plavix and a host of...
Amgen Upgraded to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 3:40PM CDT
On Aug 21, Zacks Investment Research upgraded Amgen Inc. (AMGN) to a Zacks Rank #1 (Strong Buy).
Gilead Sciences Set to Possibly Pullback After Yesterday's Rally of 1.65%
Comtex SmarTrend(R) - Fri Aug 22, 3:37PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $102.61 to a high of $105.16. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $102.57 on volume of 13.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Look for Shares of Gilead Sciences to Potentially Pullback after Yesterday's 1.65% Rise
Comtex SmarTrend(R) - Fri Aug 22, 3:36PM CDT
Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $102.61 to a high of $105.16. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $102.57 on volume of 13.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Midday Glance: Biotechnology companies
AP - Fri Aug 22, 12:22PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Next Resistance Level for Gilead Sciences (GILD) is $103.26
Comtex SmarTrend(R) - Fri Aug 22, 9:02AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) have bullishly opened above the pivot of $101.81 today and have reached the first resistance level of $102.77. Investors may be interested in a cross of the next upside pivot targets of $103.26 and $104.71.
Repros Therapeutics (RPRX) Shows Strength: Stock Rises 5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 8:39AM CDT
Repros Therapeutics Inc. (RPRX) was a big mover last session, as its shares rose a little over 5% on the day.
Why Gilead Sciences (GILD) Could Beat Earnings Estimates Again - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 7:49AM CDT
Gilead Sciences has seen a nice streak of beating earnings estimates at the previous two reports, suggesting it has a nice short-term history of crushing expectations and that it could be a great candidate for another beat.
Jim Cramer's 'Mad Money' Recap: 12 Stocks Even Better Than Google
at The Street - Thu Aug 21, 6:59PM CDT
Google is fabulous, Cramer says, but these stocks are just as good if not better.
Bristol-Myers, Celgene Pair Up for Oncology Combo Treatments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 4:20PM CDT
Bristol-Myers (BMY) inked an oncology deal with Celgene (CELG).
Achillion Attains 52-Week High on ACH-3102 Patent Protection - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 4:00PM CDT
Achillion's (ACHN) shares touched a 52-week high of $10.18 on Aug 20 following its announcement that the USPTO has granted a patent to the company.
Amicus Therapeutics (FOLD) Soars on Fabry Drug Trial Results - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 21, 3:55PM CDT
Amicus Therapeutics (FOLD) announced positive data from its second phase III study on migalastat.
Jim Cramer's Stop Trading: Don't Worry About Gilead Sciences
at The Street - Thu Aug 21, 10:10AM CDT
TheStreet's Jim Cramer says investors should not worry about Gilead Sciences, especially considering its low valuation.
